The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity
Open accessPublished version of a preprint
Abstract
Bivalent proteolysis-targeting chimeras (PROTACs) drive protein degradation by simultaneously binding a target protein and an E3 ligase and forming a productive ternary complex. We hypothesized that increasing binding valency within a PROTAC could enhance degradation. Here, we designed trivalent PROTACs consisting of a bivalent bromo and extra terminal (BET) inhibitor and an E3 ligand tethered via a branched linker. We identified von Hippel-Lindau (VHL)-based SIM1 as a low picomolar BET degrader with preference for bromodomain containing 2 (BRD2). Compared to bivalent PROTACs, SIM1 showed more sustained and higher degradation efficacy, which led to more potent anticancer activity. Mechanistically, SIM1 simultaneously engages with high avidity both BET bromodomains in a cis intramolecular fashion and forms a 1:1:1 ternary complex with VHL, exhibiting positive cooperativity and high cellular stability with prolonged residence time. Collectively, our data along with favorable in vivo pharmacokinetics demonstrate that augmenting the binding valency of proximity-induced modalities can be an enabling strategy for advancing functional outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Researchers discovered that the degradation efficacy of PROTACs is influenced by valence number. The trivalent PROTAC named SIM1, developed by Satomi Imaide’s team, exhibited significantly enhanced degradation compared to its divalent counterpart.521”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [521]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Self-citationLysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
Self-citationLessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923
Synthetic Multivalent Ligands as Probes of Signal Transduction
Kiessling, L. L., Gestwicki, J. E., & Strong, L. E. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502794 · Cited by 864
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 830
Cited by
Sorted by citations
Items 201–252 of 252
Gu, J., He, M., Wang, W., Hu, J., Yang, X., Lai, M., Li, S., Duan, X., Luo, Q., & Zhang, G. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105384 · Cited by 1
Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States
Corrionero, A., Prendiville, N., Cazorla, T., Baena-Nuevo, M., Röhm, S., Camafeita, E., Knapp, S., & Alfonso, P. (2026) · ChemMedChem · doi:10.1002/cmdc.70331 · Cited by 1
Nevins, S., McLoughlin, C. D., Ko, W., Choi, H. K., Conklin, B., Stein, J. B., Hou, Y., Kim, H., Khulbe, R., & Lee, K. (2026) · Advanced Functional Materials · doi:10.1002/adfm.76374 · Cited by 1
Xin, L., Liu, J., Guo, X., Li, S., Guo, Z., Wang, H., Song, Z., Deng, X., Wang, C., Fang, P. H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01189 · Cited by 1
Proteolysis targeting chimeras for drug discovery from mechanistic basis to clinical translation
Badadhe, S. G., Gawali, V. B., Bhalsing, M. D., & Jangme, C. (2026) · Discover Chemistry. · doi:10.1007/s44371-026-00963-4 · Cited by 1
Targeting SHP2 for Cancer Treatment: Advances and Prospects
Song, Y., & Yu, B. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_256-1 · Cited by 1
Peptide-based inhibitors of epigenetic proteins
Hintzen, J. C. J., & Mecinović, J. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.04.004 · Cited by 1
Substrate recognition by Cullin-RING ubiquitin ligase and chemical intervention
Xu, C., Fan, X., Gao, X., & Qi, W. (2024) · Scientia Sinica Chimica · doi:10.1360/ssc-2024-0242 · Cited by 1
Mo, M., Wang, F., Zhang, H., Zhang, Y., Yang, C. J., Shang, J., & Zhu, Z. (2025) · Angewandte Chemie · doi:10.1002/ange.202501857 · Cited by 1
Cacabelos, R., Naidoo, V., Tellado, I., Corzo, L., Cacabelos, N., Cacabelos, P., Martínez-Iglesias, O. A., & Segre, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00029-3 · Cited by 1
Nanoparticle-mediated delivery of peptide-based degraders enables targeted protein degradationPreprint
Alabi, C. A., Ghosal, S., Robertus, C. M., Wang, J., Chan, H., Alamgir, A., & Almonte, J. (2024) · Research Square · doi:10.21203/rs.3.rs-3797623/v1 · Cited by 1
A Reliable and Sustainable Multicomponent Access to Protein DegradersPreprint
Bhela, I. P., Ranza, A., Serafini, M. T., & Pirali, T. (2021) · doi:10.33774/chemrxiv-2021-440t2-v2
The Future of Heterobifunctional Compounds: PROTACs and Beyond
Burslem, G. M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch10
A Structural and Biophysical Perspective of Degrader Activity Through Ternary Complex Formation
Gadd, M. S., & Aublette, M. C. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch4
PROTAC Pharmaceutical Research and its Applications
Xu, Y. (2023) · International Journal of Biology and Life Sciences · doi:10.54097/ijbls.v2i3.8663
Simple and Efficient Synthesis of Piperidine-2,6-DionesPreprint
Liu, Y., Xue, Z., Yang, K.-W., Yin, H., Wang, T., Guan, Y., Ligang, Y.-F., Zhong, H., & Bai, Z. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4659363
New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery
Valeur, E. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00911
Unveiling the Power of PROTAC Valency: Navigating Cell Type-Specific Hook EffectsPreprint
Chitsazan, A., Eisele, F., Rabieifar, P., Park, H., Nordberg, M., Liu, J., Geschwindner, S., & Dahl, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.12.598404
A Comprehensive Overview of Protacs Targeting Hsp90 and Their Client Proteins for Cancer TherapyPreprint
Kumar, G., Tyagi, G., & Monga, V. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5125761
Simplified Maxwell-Boltzmann-Hansch Function (SMBH function) and its Application in PROTACPreprint
Cao, X., Wu, K., Qu, J., Jiang, L., Li, Y., Guo, Y., Liu, D., & Peng, X. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5066556
Heterobifunctional proteomimetic polymers for targeted protein degradationPreprint
Wang, M. M., Truica, M. I., Gattis, B. S., Oktawiec, J., Sagar, V., Basu, A. A., Bertin, P. A., Zhang, X., Abdulkadir, S. A., & Gianneschi, N. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.07.641543
Targeting SHP2 for Cancer Treatment: Advances and Prospects
Song, Y., & Yu, B. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_256
PROTACs as New Tools to Study Platelet Function
Trory, J. S., May, C., & Hers, I. (2025) · Springer eBooks · doi:10.1007/978-3-031-96344-5_27
PROTACS- targeted protein degradation as a path to precision cancer therapeutics
Gatley, H. R., Fisher, P. B., & Das, S. K. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.08.001
Liu, S., Cheng, D., Peng, C., Wu, Y., Xiang, J., Zhou, D., Jin, H., Zhan, Q., Cao, P., & Cao, T. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c04455
Liu, Y., Wu, J., Chen, D., & Han, L. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00381
Protacs Targeting ERα in the Effective Management of Endocrinal Resistance Breast Cancer
Singh, A., Khan, R., Erachampatt, N. A., Bhatia, N., Monga, V., & Thareja, S. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70176
Dual Target E3 Ligase Ligands: A New Way to Overcome Drug Resistance
潘, 相. (2026) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2026.141006
Xu, Y., Wang, S., Saneyoshi, H., Fujita, H., & Nagasawa, K. (2026) · Research Square · doi:10.21203/rs.3.rs-9143133/v1
A Cu(I)-catalysed click reaction generates ROS-triggered cleavable linkages in aqueous media
Hackey, M. E., Formica, M., Bauer, V., Alavijeh, N. S., Fu, Y., Naudin, E. A., Nikbakht, A., Yassine, D., Paioti, P. H. S., del Pozo, J., et al. (2026) · Nature Chemistry · doi:10.1038/s41557-026-02100-1
Wu, X., Gao, J., Ding, F., Suo, D., & Pan, G. (2026) · Engineered Regeneration · doi:10.1016/j.engreg.2026.05.002
Nassar, H., Schmidt, M., Ibrahim, H. S., Robaa, D., & Sippl, W. (2026) · Journal of Cheminformatics · doi:10.1186/s13321-026-01268-5
Wang, C., Xu, B., Xin, L., Guo, Z., Deng, X., Dong, C., Yang, J., & Zhou, H. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00521
From affinity to kinetics: SPR as the analytical backbone of AI-driven drug discovery
Hwang, Y., Kim, J., Ko, J. B., Han, Y., Kim, Y., Lee, K. H., & Jang, S. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.119089
Techniques for Accelerating the Understanding of PROTAC-Based Ternary Complex
Ullah, I., Gao, J., & Yuan, Y. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_840
Peng, L., Li, Q., Li, Z., Bai, G., Tian, Y., & Zhou, S. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c11943
Wu, X., Xiao, Y., Song, Z., Zhang, H., Yin, L., Fang, N., & Zhu, Q. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.182897
The bromodomain and its contribution to human health
Linteau, N., & Lambert, J.-P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-19001-8.00008-8
Wang, T., Ji, C., & Zhao, T. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1967704
Zhan, J., Ye, Y., Liu, G., Dong, X., & Zhang, J. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.183381
BindingDB (2026) · UC San Diego · doi:10.7270/q2xg9wzj
BindingDB (2025) · UC San Diego · doi:10.7270/q2ws8zww
BindingDB Entry 50018681: A comprehensive review of BET-targeting PROTACs for cancer therapy.
BindingDB (2024) · UC San Diego · doi:10.7270/q2930zdd
BindingDB Entry 50018797: A bibliometric analysis of PROTAC from 2001 to 2021.
BindingDB (2024) · UC San Diego · doi:10.7270/q28p64s7
BindingDB Entry 50016243: Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.
BindingDB (2023) · UC San Diego · doi:10.7270/q2x92g9p
Metadata
- Authors
- Imaide, S., Riching, K. M., Makukhin, N., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N., Mahan, S. D., Murphy, N., Cowan, A. D., Chan, K.-H., Craigon, C., Testa, A., Maniaci, C., Urh, M., Daniels, D. L., & Ciulli, A.
- Affiliations
- University of Dundee (GB)
- Promega (United States) (US)
- Corresponding author
- Daniels, Danette L.
- Ciulli, Alessio
- ORCID
- Venue
- Nature Chemical Biology
- Published
- 2021-10-21
- Volume
- 17
- Issue
- 11
- Pages
- 1157-1167
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC7611906
- OpenAlex
- W3205001044
- Semantic Scholar
- 8e332350826646e57b57de209660d026df6f461d
- Cited by
- 251
- References
- 62
- Citations by year
- 2026: 38 · 2025: 59 · 2024: 57 · 2023: 45 · 2022: 44 · 2021: 8
- FWCI
- 12.33
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Nature Chemical Biology (publishedVersion)
- Research Square (acceptedVersion, cc-by)
- ChemRxiv (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Wellcome Trust (094090/Z/10/Z, strategic awards to Dundee 100476/Z/12/Z and 094090/Z/10/Z, 100476/Z/12/Z)
- Ono Pharmaceutical
- European Research Council (Starting Grant ERC-2012-StG-311460 DrugE3CRLs)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- protein degradation, BET inhibitors, SIM1, BRD2, avidity, positive cooperativity, ternary complex, anticancer activity, pharmacokinetics
- MeSH terms
- Humans, Ubiquitin-Protein Ligases, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
